23 completed, 7 terminated, 5 active not recruiting, 1 recruiting. 19 Phase 2, 17 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Recurrent Renal Cell Carcinoma: new trials by email Literature Review of Recurrent Renal Cell Carcinoma trials Research Report on Recurrent Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) NKT2152, palbociclib, sasanlimab - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | NiKang Therapeutics, Inc. | 18 | 2023-07-28 | 2025-11-12 |
| Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography - Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 2 | Recruiting | john eisenbrey | 210 | 2022-11-03 | 2026-02-17 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Oral NKT2152 - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | NiKang Therapeutics, Inc. | 120 | 2021-10-26 | 2025-11-12 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis - Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer | Phase 2 | Active not recruiting | University of Southern California | 62 | 2017-07-19 | 2026-06-03 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma | Early Phase 1 | Completed | Mayo Clinic | 2 | 2016-01-01 | 2019-06-06 |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer Computed Tomography, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Healthy Subject, Metastatic Renal Cell Cancer | Active not recruiting | University of Southern California | 37 | 2015-09-08 | 2026-04-02 | |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer Stereotactic Body Radiation Therapy - Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma | Not applicable | Terminated | University of Chicago | 25 | 2015-05-01 | 2024-05-30 |
| Immunotherapy Study for Metastatic Renal Cell Cancer HyperAcute®-Renal (HAR) Immunotherapy - Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer | Phase 1 | Completed | NewLink Genetics Corporation | 18 | 2015-05-01 | 2022-04-06 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 59 | 2015-04-08 | 2026-10-07 |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Radiation Therapy (RT), MK-3475 - Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 41 | 2015-02-05 | 2025-05-15 |
| Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer Laboratory Biomarker Analysis, Nephrectomy, Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003 - Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer | Not applicable | Terminated | Roswell Park Cancer Institute | 5 | 2014-10-14 | 2020-07-07 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Pazopanib Hydrochloride - Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma | Phase 2 | Completed | Mayo Clinic | 38 | 2013-05-16 | 2025-03-03 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15 - Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2013-02-15 | 2017-09-15 |
| Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2012-11-01 | 2018-08-28 |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib - Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2012-08-20 | 2019-01-03 |
Showing 20 of 37. Sign in to see all of them.
Carcinoma, Renal Cell (37) · Melanoma (9) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (5) · Ovarian Neoplasms (5) · Colorectal Neoplasms (4) · Lung Neoplasms (4) · Prostatic Neoplasms (4) · Sarcoma (4) · Urinary Bladder Neoplasms (4) · Carcinoma, Hepatocellular (3) · Kidney Neoplasms (3) · Pancreatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3)
Female Urogenital Diseases (37) · Female Urogenital Diseases and Pregnancy Complications (37) · Male Urogenital Diseases (37) · Neoplasms by Histologic Type (37) · Urogenital Diseases (37) · Adenocarcinoma (36) · Carcinoma (36) · Kidney Diseases (36) · Neoplasms by Site (36) · Neoplasms, Glandular and Epithelial (36) · Urogenital Neoplasms (36) · Urologic Diseases (36) · Urologic Neoplasms (36) · Neoplasms (35) · Kidney Neoplasms (34)
Bevacizumab (5) · Disulfides (4) · Immunoglobulin G (4) · Magnetic Resonance Spectroscopy (4) · Sorafenib (4) · Sirolimus (3) · Specimen Handling (3) · pembrolizumab (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Biopsy (2) · Everolimus (2) · Nivolumab (2) · Sunitinib (2) · cabozantinib (2) · cediranib (2)
National Cancer Institute (NCI) (21) · Mayo Clinic (3) · Roswell Park Cancer Institute (3) · NiKang Therapeutics, Inc. (2) · University of Southern California (2) · City of Hope Medical Center (1) · NewLink Genetics Corporation (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Chicago (1) · john eisenbrey (1)
United States (33) · Canada (6) · Australia (1) · Netherlands (1) · Peru (1) · Taiwan (1)
Eric Jonasch (2) · Biren Saraiya (1) · Brian Costello, M.D. (1) · Charles B Nguyen (1) · Christian Kollmannsberger (1) · Frank S Hodi (1) · George Philips (1) · Glenn Liu (1) · Haiying Cheng (1) · Jacek Pinski, MD (1) · Jeffrey Miller (1) · Jeffrey Sosman (1) · Jennifer Johnson, MD, PhD (1) · John Sarantopoulos (1)
PMID 25900027, PMID 26077237, PMID 27663515, PMID 29203590, PMID 30045932, PMID 31401903, PMID 32043778, PMID 35264434, PMID 35780243, PMID 36848607, PMID 37146227, PMID 38236249, PMID 39462179, PMID 39863139, PMID 40132910, PMID 40451439, PMID 42847673
U01CA132123 (3), UM1CA186644 (3), N01CM00038 (2), N01CM00039 (2), N01CM62202 (2), P30CA014089 (2), P30CA015083 (2), P30CA016056 (2), P30CA016672 (2), P30CA033572 (2), N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM62203 (1), N01CM62204 (1)